Abstract:Objective: This randomized, double-blind 8 week study compared the efficacy and tolerability of fixed-dose treatment with vortioxetine (10 mg/day) and venlafaxine extended release (XR) (150 mg/day) in major depressive disorder (MDD) patients. Research design and methods: Patients aged 18-65 years with a primary diagnosis of recurrent MDD, a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26 and a Clinical Global Impression-Severity (CGI-S) score ≥4 were randomized (1:1) to treatment with either vortioxetine or venlafaxine XR. The primary endpoint was change from baseline to Week 8 in MADRS total score (analysis of covariance [ANCOVA], full-analysis set [FAS], last observation carried forward [LOCF]), using a non-inferiority margin of +2.5 points. Pre-specified secondary endpoints included MADRS response and remission rates, anxiety symptoms (HAM-A), CGI, overall functioning (SDS), and health-related quality of life (Q-LES-Q). Clinical trial registration: This study (SOLUTION) has the www.ClinicalTrials.gov identifier: NCT01571453. Results: On the primary efficacy endpoint at Week 8, non-inferiority was established with a difference of -1.2 MADRS points in favor of vortioxetine (95% CI: -3.0 to 0.6). The MADRS total score decreased (improved) from 32.3 ± 4.6 at baseline to 13.6 ± 9.6 (vortioxetine: n = 209) and from 32.3 ± 4.5 to 14.8 ± 10.4 (venlafaxine XR: n = 215) (FAS, LOCF). At Week 8, the HAM-A and SDS total scores, CGI and Q-LES-Q scores, and response and remission rates demonstrated similar improvement for vortioxetine and venlafaxine XR, with remission rates (MADRS ≤10) of 43.1% (vortioxetine) versus 41.4% (venlafaxine XR) (LOCF). Fewer vortioxetine than venlafaxine XR patients withdrew for any reason (18.0% versus 27.4%) or for adverse events (6.6% versus 13.7%). The most frequent adverse events (≥5%) for both treatments were nausea, dizziness, headache, and dry mouth. In addition, accidental overdose, decreased appetite, constipation and insomnia were reported by (≥5%) of patients treated with venlafaxine XR. Limitations: The inclusion and exclusion criteria may limit the generalizability of the study. Since patients with a history of lack of response to venlafaxine XR were excluded from this study, there is a selection bias in favor of venlafaxine XR. Conclusion: Vortioxetine was at least as efficacious as venlafaxine XR and was safe and better tolerated than venlafaxine XR.

Comparison of Reboxetine with Fluoxetine in Treatment of Depression: a Randomized, Double-Blind, Multicenter Study

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

A Randomized and Double-Blind Comparison with Reboxetine and Citalopram in Patients with Retardant Depressive Disorder

Clinical effect of reboxetine in the treatment of anxiety in depressive patients

The efficacy and safety of venlafaxine XR in treating patients with major depression in a multicenter,open-label, 16 week study

Efficacy and safety of olanzapine combined with fluoxetine in treatment of depression

Comparison of Escitalopram with Citalopram in Treatment of Depression: a Randomized, Double-Blind, Multicenter Study

Study of Bupropion Hydrochloride Tablet and Fluoxetine in Treatment of Depression Multicenter Clinical Trial

Treatment with Bupropion Sustained Release Tablet in Patients with Depression:A Randomized,double-Blind,multi-center Clinical Trial

Bupropion-sustained release in treatment of depression (72 patients) : a randomized, double-blind, doubledummy, multi-center clinical trial

Efficacy and Safety of Bupropion Hydrochloride Extended-Release Versus Escitalopram Oxalate in Chinese Patients with Major Depressive Disorder: Results from a Randomized, Double-Blind, Non-Inferiority Trial.

Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study

Escitalopram Vs Citalopram: a Parallel Controlled Study for Depression

Repetitive Transcranial Magnetic Stimulation In Combination With Citalopram In Young Patients With First-Episode Major Depressive Disorder: A Double-Blind, Randomized, Sham-Controlled Trial

Control study of mirtazapine and fluoxetine in therapy of depression

Fluoxetine Enteric Tablet Versus Fluoxetine in Continuation Treatment of Major Depressive Disorder:A Multicentre Randomized Double-Blind Controlled Study

[Repetitive Transcranial Magnetic Stimulation Combined with Antidepressant Medication in Treatment of First-Episode Patients with Major Depression].

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

ComParison of different treatment regimens for refractory dePression efficacy

Duloxetine Versus Paroxetine in the Treatment of Major Depressive Disorder: a Randomized Double-Blind Multicentre Controlled Study